Literature DB >> 26691569

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits.

Kimia Kardani1, Azam Bolhassani2, Sepideh Shahbazi1.   

Abstract

The essential goal of vaccination is to generate potent and long-term protection against diseases. Among different vaccine modalities, prime-boost vaccine strategies could enhance cellular and also humoral immunity in several animal models. These strategies have been applied for the development of vaccines against important infectious diseases such as HIV, SIV, HCV, HSV, and HBV indicating promising results even in clinical trials. Several factors including selection of antigen, type of vector, delivery route, dose, adjuvant, boosting regimen, the order of vector injection, and the intervals between different vaccinations influence the outcome of prime-boost immunization approaches. The reported data suggest that the prime-boost strategy as a combination of vaccines (i.e., heterologous prime-boost) may be better than a single vaccine for protection against infectious diseases. Indeed, in many cases, heterologous prime-boost can be more immunogenic than homologous prime-boost strategy. This review discusses the recent advances in prime-boost immunization strategies as well as their benefits and mechanisms of action.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Infectious disease; Mechanism of action; Prime-boost vaccination

Mesh:

Substances:

Year:  2015        PMID: 26691569     DOI: 10.1016/j.vaccine.2015.11.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  72 in total

1.  Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.

Authors:  Jean-Louis Palgen; Nicolas Tchitchek; André Rodriguez-Pozo; Quentin Jouhault; Hadjer Abdelhouahab; Nathalie Dereuddre-Bosquet; Vanessa Contreras; Frédéric Martinon; Antonio Cosma; Yves Lévy; Roger Le Grand; Anne-Sophie Beignon
Journal:  NPJ Vaccines       Date:  2020-03-19       Impact factor: 7.344

2.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

Authors:  Mariane Melo; Ely Porter; Yuan Zhang; Murillo Silva; Na Li; Brian Dobosh; Alessia Liguori; Pat Skog; Elise Landais; Sergey Menis; Devin Sok; David Nemazee; William R Schief; Ron Weiss; Darrell J Irvine
Journal:  Mol Ther       Date:  2019-08-19       Impact factor: 11.454

Review 3.  Vaccinations for Neuroinfectious Disease: A Global Health Priority.

Authors:  Emily C Leibovitch; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  Noninvasive vaccination as a casus belli to redeem vaccine value in the face of anti-vaccine movements.

Authors:  De-Chu C Tang
Journal:  Integr Mol Med       Date:  2017-07-24

5.  Zika virus-an update on the current efforts for vaccine development.

Authors:  Victória Alves Santos Lunardelli; Juliana De Souza Apostolico; Edgar Ruz Fernandes; Daniela Santoro Rosa
Journal:  Hum Vaccin Immunother       Date:  2020-08-11       Impact factor: 3.452

6.  Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques.

Authors:  Michael K McCracken; Caitlin H Kuklis; Chandrika B Kannadka; David A Barvir; Mark A Sanborn; Adam T Waickman; Hayden C Siegfried; Kaitlin A Victor; Kristin L Hatch; Rafael De La Barrera; Shannon D Walls; Wiriya Rutvisuttinunt; Jeffrey R Currier; Heather Friberg; Richard G Jarman; Gregory D Gromowski
Journal:  NPJ Vaccines       Date:  2021-05-21       Impact factor: 7.344

7.  A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.

Authors:  Eun Kim; Florian J Weisel; Stephen C Balmert; Muhammad S Khan; Shaohua Huang; Geza Erdos; Thomas W Kenniston; Cara Donahue Carey; Stephen M Joachim; Laura J Conter; Nadine M Weisel; Nisreen M A Okba; Bart L Haagmans; Elena Percivalle; Irene Cassaniti; Fausto Baldanti; Emrullah Korkmaz; Mark J Shlomchik; Louis D Falo; Andrea Gambotto
Journal:  Eur J Immunol       Date:  2021-05-06       Impact factor: 6.688

8.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Authors:  Alberto M Borobia; Antonio J Carcas; Mayte Pérez-Olmeda; Luis Castaño; María Jesús Bertran; Javier García-Pérez; Magdalena Campins; Antonio Portolés; María González-Pérez; María Teresa García Morales; Eunate Arana-Arri; Marta Aldea; Francisco Díez-Fuertes; Inmaculada Fuentes; Ana Ascaso; David Lora; Natale Imaz-Ayo; Lourdes E Barón-Mira; Antonia Agustí; Carla Pérez-Ingidua; Agustín Gómez de la Cámara; José Ramón Arribas; Jordi Ochando; José Alcamí; Cristóbal Belda-Iniesta; Jesús Frías
Journal:  Lancet       Date:  2021-06-25       Impact factor: 79.321

Review 9.  Pollution, Inflammation, and Vaccines: A Complex Crosstalk.

Authors:  Laura Franza; Rossella Cianci
Journal:  Int J Environ Res Public Health       Date:  2021-06-11       Impact factor: 3.390

10.  Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses.

Authors:  Ulrike Sauermann; Antonia Radaelli; Nicole Stolte-Leeb; Katharina Raue; Massimiliano Bissa; Carlo Zanotto; Michael Krawczak; Matthias Tenbusch; Klaus Überla; Brandon F Keele; Carlo De Giuli Morghen; Sieghart Sopper; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2017-11-14       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.